Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 6/20 | 0.53 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696160 | 0.81 | NPC1 (0.55) | NPC1MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL1754377 | 0.80 | TAS2R14 (0.50) | MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4294807 | 0.76 | CCNB2 (0.55) | MAPT | |
| SCHEMBL13006162 | 0.76 | ERN1 (0.43) | SLC2A1LPAR1NPC1MAPTALDH1A1 | |
| SCHEMBL19511901 | 0.75 | ERN1 (0.60) | NPC1ALDH1A1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5628749 | 0.75 | ALDH1A1 (0.64) | NPC1MAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL3446415 | 0.73 | ALDH1A1 (0.54) | NPC1MAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL19512012 | 0.73 | NPC1 (0.45) | NPC1MAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL9597698 | 0.72 | RAB9A (0.52) | NPC1KMT2ARAB9A | |
| SCHEMBL29952390 | 0.72 | KMT2A (0.64) | NPC1MAPTALDH1A1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2013-12-26 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | SLC2A1 1549/4885SLC2A4 1816/4885LPAR1 78/4885 |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | NR1H2, NR1H3, NR1H4 | SLC2A1 1549/4885SLC2A4 1816/4885LPAR1 78/4885 |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | SLC2A1 1549/4885SLC2A4 1816/4885LPAR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.